Significant Dose Effect of Carbamazepine on Reduction of Steady-State Plasma Concentration of Haloperidol in Schizophrenic Patients
暂无分享,去创建一个
[1] L. Bertilsson,et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. , 2003, British journal of clinical pharmacology.
[2] A. Suzuki,et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes , 2002, Psychopharmacology.
[3] E. Perucca,et al. Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs , 2002, Epilepsia.
[4] N. Yasui-Furukori,et al. Carbamazepine Decreases Antihypertensive Effect of Nilvadipine , 2002, Journal of clinical pharmacology.
[5] J. Swanson,et al. Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states. , 2000, Experimental and clinical psychopharmacology.
[6] P. Czobor,et al. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. , 1999, Journal of clinical psychopharmacology.
[7] C. Normann,et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. , 1999, Journal of clinical psychopharmacology.
[8] K. Otani,et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. , 1999, Journal of clinical psychopharmacology.
[9] C. Eap,et al. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. , 1999, Therapeutic drug monitoring.
[10] K. Otani,et al. Effects of the CYP2D6*10 allele on the steady‐state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia , 1999, Clinical pharmacology and therapeutics.
[11] M. Odomi,et al. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation , 1998, European Journal of Clinical Pharmacology.
[12] G. Anderson. A Mechanistic Approach to Antiepileptic Drug Interactions , 1998, The Annals of pharmacotherapy.
[13] K. Otani,et al. Effect of Carbamazepine on the Single Oral Dose Pharmacokinetics of Alprazolam , 1998, Neuropsychopharmacology.
[14] K. Otani,et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. , 1997, Pharmacogenetics.
[15] P. Silverstone,et al. Involvement of CYP3A4 and CYP2D6 in the Metabolism of Haloperidol , 1997, Cellular and Molecular Neurobiology.
[16] K. Otani,et al. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. , 1996, Therapeutic drug monitoring.
[17] K. Otani,et al. Carbamazepine augmentation therapy in three patients with trazodone‐resistant unipolar depression , 1996, International clinical psychopharmacology.
[18] R. Baldessarini,et al. Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. , 1995, The American journal of psychiatry.
[19] M. W. Tsang,et al. Metabolism of haloperidol: clinical implications and unanswered questions. , 1994, Journal of clinical psychopharmacology.
[20] T. Someya,et al. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. , 1992, Journal of clinical psychopharmacology.
[21] C. Alm,et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. , 1992, Therapeutic drug monitoring.
[22] S. Schulz,et al. Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia. , 1990, Journal of clinical psychopharmacology.
[23] Y. Ohkura,et al. Determination of Pranoprofen in Serum by Automated Column-Switching High-Performance Liquid Chromatography , 1989 .
[24] M. Jann,et al. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation , 1989, Psychiatry Research.
[25] G. Simpson,et al. A carbamazepine trial in chronic, treatment-refractory schizophrenia. , 1988, The American journal of psychiatry.
[26] H. Emrich,et al. Carbamazepine as an adjunct of antipsychotic therapy , 1987, Psychiatry Research.
[27] U. Ahlfors,et al. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.
[28] D. Goff,et al. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? , 1986, The American journal of psychiatry.
[29] C. Bowden,et al. Effects of carbamazepine on plasma haloperidol levels. , 1985, Journal of clinical psychopharmacology.
[30] R. Belmaker,et al. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia , 1985, Biological Psychiatry.
[31] Tokijiro Sato,et al. Time‐Dependency of Serum Carbamazepine Concentration , 1978, Folia psychiatrica et neurologica japonica.
[32] M. Jann,et al. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients , 2005, Psychopharmacology.
[33] S. Caccia. Biotransformation of post-clozapine antipsychotics: pharmacological implications. , 2000, Clinical pharmacokinetics.
[34] K. Otani,et al. Interaction between carbamazepine and bromperidol , 1997, European Journal of Clinical Pharmacology.
[35] J. Lindenmayer,et al. Psychopathology of Schizophrenia: initial validation of a 5-factor model. , 1995, Psychopathology.
[36] R. Poland,et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. , 1992, The American journal of psychiatry.
[37] Y. Ohkura,et al. Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography. , 1989, Journal of chromatography.
[38] P Bech,et al. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. , 1986, Acta psychiatrica Scandinavica. Supplementum.